Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc. over the past decade.

Apellis Pharmaceuticals, Inc.

From 2014 to 2023, Apellis Pharmaceuticals has seen a staggering increase in SG&A expenses, growing from a modest $2.9 million to an impressive $500 million. This represents a growth of over 17,000%, highlighting the company's aggressive expansion and investment in administrative capabilities.

ImmunityBio, Inc.

In contrast, ImmunityBio's SG&A expenses peaked in 2015 at $226 million but have since stabilized, with 2023 figures at approximately $130 million. This trend suggests a more conservative approach to administrative spending, possibly reflecting strategic shifts or operational efficiencies.

These spending patterns offer a window into each company's strategic priorities and market positioning, providing valuable insights for potential investors.